2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Podoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.Peer-Reviewed Original ResearchConceptsIncidence of thrombosisPolycythemia veraEssential thrombocythemiaStatin useOlder adultsEnd Results-Medicare databasePopulation-based cohort studyArterial thrombotic eventsSurvival of patientsUse of statinsClaims-based studyRisk of thrombosisCardiovascular morbidityCause mortalityTreatment weighting (IPTW) approachCohort studyOlder patientsOverall survivalThrombotic eventsVenous thrombosisPatient populationPrevious registryStatinsTherapeutic strategiesET subgroupThe COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021
Goyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Network Open 2023, 6: e2316642. PMID: 37273206, PMCID: PMC10242428, DOI: 10.1001/jamanetworkopen.2023.16642.Peer-Reviewed Original ResearchConceptsEarly pandemic monthsOral therapyOutpatient infusionsChronic lymphocytic leukemiaHematologic neoplasmsVisit ratesTelemedicine useCohort studyPandemic monthsLymphocytic leukemiaRetrospective observational cohort studyData cutoff datePerson medical careSubsequent cancer outcomesHalf of patientsObservational cohort studyMantle cell lymphomaCOVID-19COVID-19 pandemicNon-Hispanic whitesMedian ageActive treatmentCancer outcomesMultiple myelomaActive patients
2021
Overall survival based on oncologist density in the United States: A retrospective cohort study
Malleshappa S, Giri S, Patel S, Mehta T, Appleman L, Huntington SF, Passero V, Parikh RA, Mehta KD. Overall survival based on oncologist density in the United States: A retrospective cohort study. PLOS ONE 2021, 16: e0250894. PMID: 33979399, PMCID: PMC8115849, DOI: 10.1371/journal.pone.0250894.Peer-Reviewed Original ResearchConceptsRetrospective cohort studyHPSA designationOverall survivalCohort studyMedian survivalPrimary careHealth professional shortage area (HPSA) designationsCare servicesShortage Area DesignationEnd Results (SEER) databaseKaplan-Meier methodMetastatic solid cancersMetastatic solid tumorsAmerican Medical Association MasterfileLog-rank testPrimary care servicesAreas of needPatients' median survivalHealth service availabilityHealth care servicesNumber of oncologistsAdult patientsInferior survivalSurveillance EpidemiologyResults databaseCost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal Of Clinical Oncology 2021, 39: 1119-1128. PMID: 33411586, DOI: 10.1200/jco.20.01849.Peer-Reviewed Original ResearchConceptsTransplant-ineligible patientsIncremental cost-effectiveness ratioFirst-line settingHealthcare costsClinical outcomesMultiple myelomaProgression-free survivalOverall survival dataUS payer perspectiveDirect healthcare costsCost-effectiveness ratioRandomized trialsDisease progressionTreatment strategiesParametric survival modelingPayer perspectiveSubsequent linesLater linesPatientsCostly treatmentIncremental costQALYSurvival dataLenalidomideMyeloma
2018
Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma
Huntington SF, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. Cancer 2018, 124: 4211-4220. PMID: 30216436, PMCID: PMC6263848, DOI: 10.1002/cncr.31688.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaOlder adultsCell lymphomaPopulation-based cohort analysisHigh-quality cancer careAnthracycline-containing regimenGuideline-adherent therapyHigh-volume providersNumber of patientsLook-back periodCytotoxic regimensSystemic therapyImproved survivalClinical outcomesReduced hospitalizationsLymphoma patientsCancer careCohort analysisMedicare beneficiariesComplex surgeryDLBCL casesLymphomaClinical volume
2016
Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study
Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study. The Prostate 2016, 77: 437-445. PMID: 27868212, PMCID: PMC5785924, DOI: 10.1002/pros.23281.Peer-Reviewed Original ResearchConceptsMDS/acute myeloid leukemiaAcute myeloid leukemiaProstate cancer patientsElderly prostate cancer patientsImpact of radiotherapyCancer patientsMyelodysplastic syndromeNational Cancer Institute's SurveillanceSubsequent myelodysplastic syndromeEnd Results-MedicareRetrospective cohort studyRole of radiotherapyInformed treatment decisionsUnderwent radiotherapyIMRT groupCohort studyPatient characteristicsMedian timeMyeloid leukemiaProstate cancerTreatment decisionsPatientsRadiotherapyMyeloid malignanciesSurgery